🇺🇸 FDA
Patent

US 12297182

Compositions comprising an urolithin compound

granted A61KA61K31/03A61K31/366

Quick answer

US patent 12297182 (Compositions comprising an urolithin compound) held by Amazentis SA expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Amazentis SA
Grant date
Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/03, A61K31/366, A61K31/37, A61K38/01